Nonsedating Alpha-2 Agonists
AssigneeAllergan, Inc.
InventorsKen Chow, Todd M. Heidelbaugh, John E. Donello, Daniel W. Gil
Life of this patent
Estimating the term…
Abstract
The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof.
Claims6
An α-2A/α-1A selective agonist, comprising a compound represented by
- or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof.
A pharmaceutical composition, comprising a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective agonist that comprises a compound represented by
- or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof.
Dependencies are inferred from the claim text.